T. Rowe Price Investment Management, Inc. Immunovant, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $164 Billion
- Q3 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Immunovant, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 5,164,698 shares of IMVT stock, worth $142 Million. This represents 0.05% of its overall portfolio holdings.
Number of Shares
5,164,698
Previous 6,878,956
24.92%
Holding current value
$142 Million
Previous $110 Million
24.36%
% of portfolio
0.05%
Previous 0.07%
Shares
6 transactions
Others Institutions Holding IMVT
# of Institutions
212Shares Held
81MCall Options Held
557KPut Options Held
704K-
Deep Track Capital, LP Greenwich, CT9.73MShares$268 Million8.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.83MShares$188 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.84MShares$161 Million2.47% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.22% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...